In the present study, we demonstrated that orphan nuclear receptor NURR1 (NR4A2), which displays an upregulation in prostate cancer, could act to promote both in vitro (cancer stemness and EMT features) and in vivo (castration resistance and metastasis capacities) oncogenic growth of prostate cancer cells via its direct transactivation of CTNNB1, resulted in increased level of activated or nuclear β-catenin and subsequent activation of Wnt/β-catenin signaling pathway in prostate cancer cells regardless of their AR expression status (Fig. 7E). The gene discussed is NR4A2; the disease is prostate cancer.